Reference Detail

Ref Type
PMID
Authors J. Diamond, G. Eckhardt, L. Gluck, M. Gutierrez, C. Peterson, R. Pila, E. Benaim
Title Phase 1 study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated P68, which prevents b-catenin translocation in advanced solid tumors
Journal Ann Oncol
Vol
Issue
Date
URL http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
Abstract Text Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 258P

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Therapy Description
Drug Name Trade Name Synonyms Drug Classes Drug Description
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable RX-5902 Phase I Actionable In a Phase I trial, RX-5902 treatment resulted in stable disease in 43% (15/35) of patients with advanced solid tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 258P; NCT02003092). detail...